BioSpace News Archive

UCB, a global biopharmaceutical company, announced that the first presentations of BIMZELX® four-year efficacy and safety data in the treatment of adults with moderate-to-severe plaque psoriasis are being shared this week at the 2024 American Academy of Dermatology Annual Meeting in San Diego, California, March 8–12.

Pelage Pharmaceuticals presented positive translational and Phase 1 clinical data demonstrating the company’s novel small molecule therapy PP405 reactivates dormant hair follicle stem cells to trigger hair growth.

Alumis Inc. announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric tyrosine kinase 2 inhibitor, for the treatment of patients with moderate-to-severe plaque psoriasis.

Amgen announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis.

Medtronic plc., a global leader in healthcare technology, shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States.

Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio – SB5, a biosimilar to Humira, and SB17, a proposed biosimilar to Stelara2 – at the 2024 American Academy of Dermatology Annual Meeting being held from March 8 to 12 in San Diego, California, United States.

Johnson & Johnson announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor.1,2 IL-23 plays a critical role in pathogenic T-cell activation in moderate-to-severe plaque psoriasis and underpins the inflammatory response in PsO and other dermatological, rheumatological and gastroenterological IL-23-mediated diseases.3,4

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis.